Amunix, 500 Ellis Street, Mountain View, CA 94043, USA.
Amunix, 500 Ellis Street, Mountain View, CA 94043, USA.
J Control Release. 2016 Oct 28;240:52-66. doi: 10.1016/j.jconrel.2015.10.038. Epub 2015 Oct 30.
XTEN™ is a class of unstructured hydrophilic, biodegradable protein polymers designed to increase the half-lives of therapeutic peptides and proteins. XTEN polymers and XTEN fusion proteins are typically expressed in Escherichia coli and purified by conventional protein chromatography as monodisperse polypeptides of exact length and sequence. Unstructured XTEN polypeptides have hydrodynamic volumes significantly larger than typical globular proteins of similar mass, thus imparting a bulking effect to the therapeutic payloads attached to them. Since their invention, XTEN polypeptides have been utilized to extend the half-lives of a variety of peptide- and protein-based therapeutics. Multiple clinical and preclinical studies and related drug discovery and development efforts are in progress. This review details the most current understanding of physicochemical properties and biological behavior of XTEN and XTENylated molecules. Additionally, the development path and status of several advanced drug discovery and development efforts are highlighted.
XTEN™ 是一类无规亲水、可生物降解的蛋白质聚合物,旨在延长治疗性肽和蛋白质的半衰期。XTEN 聚合物和 XTEN 融合蛋白通常在大肠杆菌中表达,并通过常规蛋白质色谱法进行纯化,得到精确长度和序列的单分散多肽。无规 XTEN 多肽的流体力学体积明显大于相似质量的典型球状蛋白质,从而对与其相连的治疗有效载荷赋予膨胀效应。自发明以来,XTEN 多肽已被用于延长多种基于肽和蛋白质的治疗药物的半衰期。正在进行多项临床前和临床研究以及相关的药物发现和开发工作。本综述详细介绍了对 XTEN 和 XTENylated 分子的物理化学性质和生物学行为的最新理解。此外,还突出了几项先进的药物发现和开发工作的发展路径和现状。